Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Clinical trial NCT02625961 · COMPLETED
Trial details
- NCT number
- NCT02625961
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-10
- Primary completion
- 2025-11-05
- Enrollment
- 296
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.